Solanezumab

A4DAB242 | Neurological disorders | Phase-III

Target APP

Isotype / Subclass G1 / IgG1

Company

Eli Lilly

Clinical Status Phase-III

Format Whole mAb

Synonyms

LY-2062430 LY 2062430 LY206430

pH Formulation —

IMGT PubChem (135274944) PubChem (160704163) PubChem (178103514) PubChem (347911237) PubChem (349503845) PubChem (472406764) PubChem (474488749) PubChem (474489069) PubChem (476293841) PubChem (481150519) PubChem (488294107) PubChem (505883989) Thera-SAbDab YAbS

Avg A4D Score

-0.6564

Score Range

-0.66 to -0.65

Structures

2

Avg. A4D Score per Structure

pH at Min / Max Aggregation Propensity

Structure ID	Source PDB	Seq. Identity	Avg. A4D Score	pH (Min Agg.)	pH (Max Agg.)	Score CDR	Score non-CDR
A4DAB242_4xxd_B_A	4xxd	99%	-0.6582	6.5	4.0	-0.0979	-0.7231
A4DAB242_4xxd_E_D	4xxd	99%	-0.6546	6.5	4.0	-0.1074	-0.7182

Solanezumab

Avg. A4D Score per Structure

pH at Min / Max Aggregation Propensity

Associated Structural Profiles Level 2